Combi-targeting concept: An optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia

Molecular Cancer Therapeutics

Volumn 7, Issue 5, 2008, Pages 1033-1043

  Katsoulas, Athanasia ^a   Rachid, Zakaria ^a   McNamee, James P ^c   Williams, Christopher ^b   Jean Claude, Bertrand J ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; PROTEIN BAX; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN ZRF0; PROTEIN ZRF1; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; ONCOPROTEIN; ZRF1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CELL CYCLE ARREST; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; BIOLOGICAL MODEL; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN K 562; METABOLISM; ONCOGENE;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; DACARBAZINE; DNA DAMAGE; DNA-BINDING PROTEINS; GENES, ABL; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; ONCOGENE PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 49849102220     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0179     Document Type: Article

References (31)

1. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-80.
2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
3. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-82.
4. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-84.
5. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100.
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
7. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
8. Cohen MH, Moses ML, Pazdur R. Imatinib for the treatment of chronic myelogenous leukemia: U.S. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Oncologist 2002;7:390-2.
9. Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.
10. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002;16:2190-6.
11. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-8.
12. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
13. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
14. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
15. Rachid Z, Katsoulas A, Brahimi F, Jean-Claude BJ. Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase. Bioorg Med Chem Lett 2003;13:3297-300.
16. Katsoulas A, Rachid Z, Brahimi F, McNamee J, Jean-Claude BJ. Cytokinetics and mechanism of action of AKO4: a novel nitrogen mustard targeted to bcr-abl. Leuk Res 2005;29:565-72.
17. Katsoulas A, Rachid Z, Brahimi F, McNamee J, Jean-Claude BJ. Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias. Leuk Res 2005;29:693-700.
18. Asaki T, Sugiyama Y, Hamamoto T, et al. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 2006;16:1421-5.
19. Rachid Z, Katsoulas A, Williams C, Larroque AL, McNamee J, Jean-Claude BJ. Optimization of novel combi-molecules: identification of balanced and mixed bcr-abl/DNA targeting properties. Bioorg Med Chem Lett 2007;17:4248-53.
20. Vaughan K, Tang Y, Llanos G, Horton JK, Simmonds RJ, Hickman JA, Stevens MFStu dies of the mode of action of antitumor triazenes and triazines. 6. 1-Aryl-3-(hydroxymethyl)-3-methyltriazenes: synthesis, chemistry, and antitumor properties. J Med Chem 1984;27:357- 63.
21. Brahimi F, Matheson S, McNamee J, Tari A, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by "combi- triazene" BJ2000, a new probe for the combi-targeting postulates. J Pharmacol Exp Ther 2002;303:238-46.
22. Vistica D, Skehan P, Scudiero D, Monks A, Pittam JD, Boyd MR. Tetrazolium-based assays for cellular viability: a critical examination of parameters affecting formazan production. Cancer Res 1991;15:2515-20.
23. Matheson S, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumour targeting strategy. J Pharmacol Exp Ther 2001;296:832-40.
24. Huang C, Ma W, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999;20:237-42.
25. Probin V, Wang Y, Bai A, Zhou D. Busulfan selectively induces cellular senescence but not apoptosis in WI38 fibroblasts via a p53-independent but extracellular signal-regulated kinase-p38 mitogen-activated protein kinase-dependent mechanism. J Pharmacol Exp Ther 2006;319:551-60.
26. Sanchez Garcia I, Grutz G. Tumorigenic activity of the Bcr-Abl oncogene is mediated by Bcl-2. Proc Natl Acad Sci U S A 1995;92:5287-91.
27. Takeda N, Shibuya M, Maru Y. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci U S A 1999;96:203-7.
28. Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001;8:795-806.
29. Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S-I. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells. Blood Cells Mol Dis 2003;31:11-7.
30. Goldberg Z, Levav Y, Krichevsky S, Fibach E, Haupt Y. Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage. Cell Cycle 2004;3:1188-95.
31. Stoklosa T, Slupianek A, Datta M, et al. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle 2004;3:1463-72.